Indeed, by performing preliminary analysis on 42 patients with different cancer types before their treatment with nivolumab, it has been identified that PD-L1 expression on tumor cell surface as one factor associated with the clinical activity of anti-PD-1 therapy (43). Here, PDCD1 is linked to neoplasm.